Skip to main content
FQHC Talent
Back to the news

HRSA 340B Rebate Model ICR Burden Comment Window Closes April 27, Second Window for FQHCs After April 20 Main Deadline

Federal

Issue

HRSA released a supplemental Information Collection Request (ICR) specifically on the administrative burden of the 340B Rebate Model Pilot Program. Comments on operational impact — pharmacy workflow, staff time costs, IT integration — are due April 27, 2026.

This is a distinct window from the April 20 main rebate policy comment deadline. FQHCs that missed the April 20 deadline should use this second window to document pharmacy workflow and staff time cost impact.

Burden comments can meaningfully shape the final rule's administrative mechanics.

Key points

  • Second comment window for FQHCs — focus on administrative burden, pharmacy workflow, IT integration costs
  • Burden comments can shape the final rule's operational mechanics — distinct from policy arguments

Sources for this story

Federal Register

Sources for your board packet

This story's source plus 4 related stories and their sources, ready to print for your team or board.

Free. Unlocking the packet subscribes you to Intel Brief. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.

#340b#hrsa#rebate-model#icr#burden-comment#april-27#deadline#pharmacy

Part of

Cite this analysis

FQHC Talent. (2026, April 27). HRSA 340B Rebate Model ICR Burden Comment Window Closes April 27, Second Window for FQHCs After April 20 Main Deadline. Source: Federal Register. Retrieved October 6, 2026, from https://www.fqhctalent.com/intel/hrsa-340b-rebate-icr-burden-comment-april-27

More in Risk & Compliance

Cookie notice

We use Google Analytics, Vercel Web Analytics, and Vercel Speed Insights to improve the site. Select Decline to turn them off in this browser. We honor GPC and Do Not Track. Read our Privacy Policy.